As researchers look for ways to reduce the need for animals in their studies, new alternative methods (NAMs) are an intriguing route to capture crucial safety data and help advance drug discovery and development – specifically, virtual control groups (VCGs).

Join Steve Bulera, CVP and Chief Scientific Officer for Safety Assessment and Toxicology at Charles River, as he discusses how VCGs can be a viable alternative to research models, what it would take for the industry to widely accept NAMs, and how they can revolutionize research for the future.

Show Notes

Virtual Control Groups

Sounds of Science E73: Virtual Control Groups

Modernizing Drug Development with Virtual Control Groups

Virtual Control Groups: A Data-Driven Novel Method

Revolutionizing the Future of Safety Studies

Charles River Laboratories Announces Development of Nonclinical Virtual Control Groups with Sanofi to Reduce the Use of Animals

Dr. Jared Baeten, Senior Vice President of Clinical Development and Virology Therapeutic Area Head at Gilead Sciences, joins me to discuss the incredible advancements in pre-exposure prophylaxis (PrEP) treatments in honor of World AIDS Day. What if a twice yearly shot could replace a daily pill? Listen now to learn more!

As researchers continue to look for new ways to test therapeutics in vitro, the field of biomedical engineering is offering new microphysiological systems that can reduce the need for animal models. Hear from Jeffrey Borenstein, Director of the Biomedical Engineering Centre at Draper, as he explains how it works, ways to expedite its access, and the benefits they will ultimately bring to patients.

Show Notes 
 

The Coming of Age of Organ-on-a-Chip technology

Sounds of Science E76: Multi-Organ Chip Systems

Charles River Joins Consortium to Advance Organ-on-a-Chip Technology

Bold New Approached: The Future of Organoid Intelligence

Organoids Evolve from Academic Marvel to Industrial Tool